株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ボツリヌス中毒症 : パイプライン製品の分析

Botulism - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 277749
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.08円で換算しております。
Back to Top
ボツリヌス中毒症 : パイプライン製品の分析 Botulism - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 45 Pages
概要

ボツリヌス中毒症は、稀ですが、重篤な疾患です。ボツリヌス菌と呼ばれる細菌が作る毒素(毒)が原因です。ボツリヌス菌は、土壌に自然に存在します。食物媒介のボツリヌス中毒症は、ボツリヌス毒素で汚染された食品を食べることで起こります。複視や目のかすみ、眼瞼下垂、ろれつが回らない、嚥下困難、口渇、筋力低下などの症状が見られます。治療は、抗毒素、集中治療、感染創の手術などが行われます。

当レポートでは、ボツリヌス中毒症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ボツリヌス中毒症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • CytoDel, LLC
  • Hawaii Biotech, Inc.
  • Microbiotix, Inc.
  • Molecular Targeting Technologies, Inc.
  • Nanotherapeutics, Inc.
  • Planet Biotechnology Inc.
  • XOMA Corporation

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9549IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H2 2017, provides an overview of the Botulism (Infectious Disease) pipeline landscape.

Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Botulism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Botulism (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Botulism (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 6 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Botulism (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Botulism (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Botulism (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Botulism (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Botulism (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Botulism (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Botulism - Overview
  • Botulism - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Botulism - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Botulism - Companies Involved in Therapeutics Development
  • CytoDel LLC
  • Hawaii Biotech Inc
  • Medy-Tox Inc
  • Microbiotix Inc
  • Nanotherapeutics Inc
  • XOMA Corp
  • Botulism - Drug Profiles
  • BoNT/A HcR4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • botulism [serotype C] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • botulism [serotypes A, B, C, D, E] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • botulism [serotypes A, B, E] (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Ctyo-111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NTM-1634 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OSX-400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OSX-400 Backups - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Polyclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XOMA-3AB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XOMA-3BB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Botulism - Dormant Projects
  • Botulism - Discontinued Products
  • Botulism - Product Development Milestones
  • Featured News & Press Releases
  • May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Botulism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Botulism - Pipeline by CytoDel LLC, H2 2017
  • Botulism - Pipeline by Hawaii Biotech Inc, H2 2017
  • Botulism - Pipeline by Medy-Tox Inc, H2 2017
  • Botulism - Pipeline by Microbiotix Inc, H2 2017
  • Botulism - Pipeline by Nanotherapeutics Inc, H2 2017
  • Botulism - Pipeline by XOMA Corp, H2 2017
  • Botulism - Dormant Projects, H2 2017
  • Botulism - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Botulism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top